Teva upgraded to Outperform from Market Perform at Leerink Leerink upgraded Teva to Outperform on expectations stabilizing cash flow will make the company more aggressive on acquisitions. The firm also says its multiple sclerosis survey validates the Copaxone 3x-switch. Leerink raised its price target for shares to $65 from $48.
Teva board authorizes increase in share repurchase program to $3B The Company announced today that, as authorized by the Board of Directors, it will increase its share repurchase program by $1.7 billion to $3 billion. The program has no time limitations. The Company intends to begin purchasing shares promptly.